Nuzolvence (zoliflodacin) is a first-in-class, oral antibacterial agent indicated for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents aged 12 years and older who meet weight requirements.
Zoliflodacin belongs to a novel class of spiropyrimidinetrione antibiotics and inhibits bacterial type II topoisomerase enzymes, which are essential for DNA replication in Neisseria gonorrhoeae. This distinct mechanism of action differentiates it from existing antibiotic classes and enables activity against strains resistant to currently available therapies.
Administered as a single oral dose, Nuzolvence offers a convenient, non-injectable treatment option and represents an important advancement in addressing the growing challenge of antimicrobial resistance in gonorrhea treatment.
